Emily Z. Keung, MD, AM, FACS, FSSO
Department of Surgical Oncology, Division of Surgery
About Dr. Emily Z. Keung
Dr. Keung is a surgeon-scientist and assistant professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center specializing in the care of patients with soft tissue sarcoma. Dr. Keung received her undergraduate degree from Harvard College and her medical degree from Harvard Medical School. She completed her general surgery residency and surgical critical care fellowship at Brigham and Women's Hospital/Harvard Medical School and fellowship in Complex General Surgical Oncology at MD Anderson Cancer Center. Dr. Keung also leads a translational laboratory research group focused on understanding the molecular pathogenesis and tumor immune microenvironment of 3 of the most common types of soft tissue sarcoma in adults: undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma. The goals of the Keung lab are to expand our understanding of fundamental soft tissue sarcoma biology, to identify novel therapeutic vulnerabilities and targets, to develop innovative treatment strategies, to translate these to patients through clinical trials and to improve outcomes for those with these challenging cancers.
Education & Training
Degree-Granting Education
| 2008 | Harvard Medical School, Boston, Massachusetts, MD |
| 2003 | Harvard University, Cambridge, Massachusetts, Biochemical Sciences, AB |
| 2003 | Harvard University, Cambridge, Massachusetts, Chemistry and Chemical Biology, AM |
Postgraduate Training
| 2017-2018 | T32 Research Fellowship, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Clinical Fellowship, Complex General Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2012-2014 | T32 Research Fellowship, Departments of Surgical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2012 | Clinical Fellowship, Surgical Critical Care, Brigham and Women's Hospital, Boston, Massachusetts |
| 2008-2016 | Residency, General Surgery, Brigham and Women's Hospital, Boston, Massachusetts |
Licenses & Certifications
| 2021 | Fellow, American College of Surgeons |
| 2020 | American Board of Surgery, Complex General Surgical Oncology |
| 2018 | American Board of Medical Quality, Certificate in Medical Quality |
| 2017 | American Board of Surgery, General Surgery |
| 2017 | American Board of Surgery, Surgical Critical Care |
| 2016 | Texas State Medical License |
Experience & Service
Administrative Appointments/Responsibilities
Associate Professor, Department of Surgical Oncology, The University of Texas of MD Anderson Cancer Center, 2025 - Present
Vice Chair of Research, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Assistant Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 2019 - 2025
Administrative Fellow, Complex General Surgical Oncology Fellowship, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - 2019
Education Fellow, Complex General Surgical Oncology Fellowship, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2018
Extramural Institutional Committee Activities
Member, Advisory Council for Clinical Research Leaders (ACCRL), The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Department of Surgical Oncology Clinical Trials Prioritization Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Division of Surgery Basic and Translational Science Research Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Data and Biospecimen Access Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Co-Director, Department of Surgical Oncology Ground Rounds, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Adult Soft-Tissue Sarcoma Practice Algorithm Core Development Team, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Clinical Competency Committee, Complex General Surgical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Transfusions and Blood Management Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, Anticoagulation Stewardship Program Perioperative Algorithm for Anticoagulants and Antiplatelet Agent Working Group, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, OR Subcommittee, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Member, Academic Leadership Team, The University of Texas MD Anderson Cancer Center, 2020 - Present
Senator, Faculty Senate Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, Melanoma Center Epic Efficiency Sprint Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2020
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Advisory Committee for Department of Surgical Oncology Chair Search, The University of Texas MD Anderson Cancer Center, 2020 - 2021
Member, Department of Surgical Oncology Fellowship Application Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2023
Member, MOSO 1711 Surgical Oncology Sarcoma Surgical Care Conference Program Planning Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Multifocal Diseases Work Group, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, OR Business Center Planning Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Interviewer, Complex General Surgical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Editorial Activities
Editorial Board, Surgical Oncology Insight, 2023 - Present
Associate Editor for Sarcoma Surgery, Langenbeck’s Archives of Surgery, 2023 - 2024
Editorial Board, Annals of Surgical Oncology, 2023 - 2026
Editorial Panel, American Cancer Society Liposarcoma Educational Hub, 2022 - Present
Sarcoma Section Editor, Global Medical Knowledge Alliance, 2022 - Present
Honors & Awards
| 2025 - Present | Sabin Award, The University of Texas MD Anderson Cancer Center |
| 2024 - Present | Membership to Society of University Surgeons |
| 2024 | Faculty Scholar Award, The University of Texas MD Anderson Cancer Center |
| 2023 | Top 10% Provider: Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS), MD Anderson Cancer Center |
| 2023 | Membership to Surgical Biology Club |
| 2023 | ASCO/AACR Methods in Clinical Cancer Research Workshop |
| 2023 | Robert M. Chamberlain Distinguished Mentor Award Nominee, The University of Texas MD Anderson Cancer Center Postdoctoral Association |
| 2023 | Society of Asian Academic Surgeons Visiting Professor, Association of Women Surgeons Hong Mo and Hsi Mei Chen Lectureship |
| 2022 | Women in Cancer Immunotherapy Network Leadership Institute Program, Society for Immunotherapy of Cancer |
| 2021 - 2022 | Top 1% Provider: Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS), The University of Texas MD Anderson Cancer Center |
| 2021 | Young Investigator Travel Award, Society for Immunotherapy of Cancer |
| 2019 | Junior Faculty Award, Society of Asian Academic Surgeons |
| 2019 | The Charles Balch Clinical Research Award, The University of Texas MD Anderson Cancer Center |
| 2018 | Resident/Fellow Development Award, Society of Asian Academic Surgeons |
| 2018 | Travel Award to the 21st Annual Meeting of the CSCO, Society of Surgical Oncology/Chinese Society of Clinical Oncology |
| 2018 | The Harter Prize for Excellence in Clinical Training Research, The University of Texas MD Anderson Cancer Center |
| 2018 | Thomas H. and Mayme P. Scott Fellowship in Cancer Research, The University of Texas MD Anderson Cancer Center |
| 2018 | AACR Scholar-in-Training Award in Memory of William Maness, American Association for Cancer Research |
| 2017 | The Connie and Jim Walter Endowed Fellowship Award in Sarcoma Research, The University of Texas MD Anderson Cancer Center |
| 2017 | Trainee Research Day Competition Finalist, The University of Texas MD Anderson Cancer Center |
| 2016 | Moore Award (PGY5 Resident Award), Brigham and Women’s Hospital |
| 2015 | Excellence in Teaching Award, Brigham and Women’s Hospital |
| 2015 | BWH Patient Doctor III Humanism in Teaching Award, Brigham and Women’s Hospital |
| 2014 | John A. Mannick Research Day Award, Brigham and Women’s Hospital |
| 2012 | Third Place Resident Prize Essay Competition, 93rd Annual Meeting of the New England Surgical Society, Rockport, Maine |
| 2011 | Citation for Excellence in Teaching, Tufts University School of Medicine |
| 2011 | Rudolph Vollman Award (PGY3 Resident Award), Brigham and Women’s Hospital/Faulkner Hospital |
| 2003 | Phi Beta Kappa, Alpha Iota of Massachusetts, Harvard University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Evaluation and Management of Soft tissue Sarcomas. Invited. Houston, Texas, US.
- 2025. The impact of SU2C-SARC032 on the multidisciplinary management of patients with high-risk soft tissue sarcoma. Session: Contemporary high-impact trialson surgical management of patients with sarcoma. Invited. Tampa, FL, US.
- 2024. Retroperitoneal Sarcoma. Invited. Houston, Texas, US.
- 2024. The impact of B cells in patients with soft tissue sarcoma. Invited. Houston, Texas, US.
- 2024. Window-of-opportunity trials and neoadjuvant trials. Invited. Houston, Texas, US.
- 2023. Evaluating the impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy. Invited. Houston, TX, US.
- 2022. Neoadjuvant treatment for sarcoma and studies on the microbiome in the TRANSCEND Cancer Initiative. Invited. Houston, Texas, US.
- 2021. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade. Invited. Houston, Texas, US.
- 2020. Evaluating the impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy. Invited. Houston, Texas, US.
- 2020. The impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy. Conference. Grand Rounds. Houston, TX, US.
- 2016. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. Invited. Grand Rounds. Boston, Massachusetts, US.
- 2014. Functional validation of Kruppel-like factor 6 as differentially expressed and epigenetically regulated transcription factor with novel tumor suppressor role in liposarcoma. Conference. The 20th Annual John A. Mannick Research Day. Boston, Massachusetts, US.
- 2014. The epigenome in melanoma and soft tissue sarcoma. Invited. Grand Rounds. West Roxbury, Massachusetts, US.
- 2014. The identification and characterization of MLL2, an epigenetic enzyme, as a novel tumor suppressor in melanoma. Conference. Harvard Surgery Research Day. Boston, Massachusetts, US.
- 2012. Outcome of patients with hematologic malignancy undergoing percutaneous endoscopic gastrostomy placement: a single institution experience. Conference. Harvard Surgery Research Day. Boston, Massachusetts, US.
Regional Presentations
- 2020. The impact of surveillance interval following resection of primary well differentiated liposarcoma of the retroperitoneum. Invited. Houston, Texas, US.
- 2014. Kruppel-like factor 6 (KLF6) is a differentially expressed transcription factor in well differentiated and dedifferentiated liposarcoma identified through unbiased epigenetic approaches. Conference. Residents and Fellows Research Day. Worcester, Massachusetts, US.
- 2012. Impact of immunocompromised status on outcomes in patients with necrotizing soft tissue infection. Conference. Annual Meeting. Rockport, Maine, US.
National Presentations
- 2025. Soft Tissue Sarcoma. Invited. Complex General Surgical Oncology Board Exam Review Course, US.
- 2024. The impact of B cells in patients with soft tissue sarcoma. Invited. Bethesda, Maryland, US.
- 2024. How to find and get the most out of a mentor-mentee relationship. Invited. Houston, Texas, US.
- 2024. The evolution of immunotherapy in soft tissue sarcoma treatment. Invited. Department of Surgery Grand Rounds. Lebanon, New Hampshire, US.
- 2024. The evolution and future of immunotherapy for soft tissue sarcoma. Invited. Research Town Hall, US.
- 2024. TLS as a predictive biomarker. Invited. Chicago, Illinois, US.
- 2024. Session: 2024 Clinical Investigator and Young Investigator Research Presentations. Title of talk: The impact of perioperative antibiotic prophylaxis on the gut microbiome in patients with cutaneous malignancy. Invited. Annual Meeting of the Society of Surgical Oncology. Atlanta, Georgia, US.
- 2024. Title of talk: Management of soft tissue sarcoma. Invited. Society of Surgical Oncology Virtual 2024 CGSO Board Review Course, US.
- 2023. The interactions between T-regulatory cells and B-cells as new therapeutic targets for immunotherapy in soft tissue sarcoma. Invited. Bethesda, Maryland, US.
- 2023. Major pathologic response following neoadjuvant radiation therapy +/- immune-checkpoint blockade is associated with improved survival in undifferentiated pleomorphic sarcoma. Conference. Maui, HI, US.
- 2023. Concurrent immunotherapy and radiation therapy (RT) improves pathologic treatment response compared with standard RT in undifferentiated pleomorphic sarcoma. Conference. New Orleans, LA, US.
- 2022. Stereotactic ablative radiation therapy for sarcoma lung metastases: indications for treatment and patterns of failure. Conference. Stereotactic ablative radiation therapy for sarcoma lung metastases: indications for treatment and patterns of failure. San Antonio, TX, US.
- 2022. Clinical outcomes of 160 with Merkel cell carcinoma following sentinel lymph node biopsy. Conference. Clinical outcomes of 160 with Merkel cell carcinoma following sentinel lymph node biopsy. San Diego, CA, US.
- 2022. Evaluation and management of soft tissue sarcoma. Invited. Department of Surgery Grand Rounds. Newton, Massachusetts, US.
- 2022. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers. Conference. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers. Boston, MA, US.
- 2022. Immunotherapy in sarcoma management. Invited. Immunotherapy in Sarcoma Management. Seattle, WA, US.
- 2022. Identifying gut microbial signatures associated with B-cells and tertiary lymphoid structures in the tumor microenvironment in response to immune checkpoint blockade. Conference. Identifying gut microbial signatures associated with B-cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB). Chicago, IL, US.
- 2022. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma: survival results after 2 years of follow-up and intratumoral B-cell receptor correlates. Conference. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma: survival results after 2 years of follow-up and intratumoral B-cell receptor correlates. Chicago, IL, US.
- 2022. The role of surgery in the multidisciplinary treatment of melanoma. Invited. The role of surgery in the multidisciplinary treatment of melanoma. Virtual, US.
- 2022. The interactions between T-regulatory cells and B-cells as new therapeutic targets for immunotherapy in soft tissue sarcoma. Invited. Virtual, US.
- 2022. The optimal role of radiation therapy and surgery. Invited. Invited Panelist, Session: The optimal role of radiation therapy and surgery. Seattle, WA, US.
- 2022. Neoadjuvant systemic therapy for Merkel cell carcinoma: a tertiary referral center experience. Conference. Neoadjuvant systemic therapy for Merkel cell carcinoma: A Tertiary Referral Center Experience. Dallas, TX, US.
- 2022. Sentinel lymph node biopsy and lymphadenectomy for soft tissue sarcoma – a single center experience of 86 consecutive cases. Conference. Sentinel lymph node biopsy and lymphadenectomy for soft tissue sarcoma – a single center experience of 86 consecutive cases. Houston, TX, US.
- 2022. Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Conference. Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Houston, TX, US.
- 2022. Localized and regional melanoma – case discussion. Invited. MD Anderson Physicians Network Symposium, US.
- 2022. Metastatic melanoma – case discussion. Invited. MD Anderson Physicians Network Symposium, US.
- 2021. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade. Conference. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade. Virtual Conference, US.
- 2021. Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Conference. Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Indian Wells, CA, US.
- 2021. Lumps, bumps, and sarcomas: how to manage extremity masses and avoid dangerous unplanned excisions. Invited. Virtual Conference.
- 2021. Targeted therapies in GIST. Invited. Virtual Conference, US.
- 2021. Immunotherapy. Conference. Virtual Conference, US.
- 2021. Soft tissue sarcomas. Invited. Virtual, US.
- 2021. Plastics, orthopedics, and sarcoma. Invited. 3rd Surgical Oncology Advanced Practitioner Conference. Virtual Conference, US.
- 2021. Sarculator is a good model to predict survival in resected U.S. extremity and trunk sarcoma patients. Conference. Sarculator is a Good Model to Predict Survival in Resected U.S. Extremity and Trunk Sarcoma Patients. Virtual Conference, US.
- 2020. Management of stage IV disease. Invited. Art and science of managing the new melanoma landscape. Virtual Conference, US.
- 2020. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Conference. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Virtual Meeting, US.
- 2019. A multidisciplinary approach to individualized patient care. Invited. Houston, Texas, US.
- 2019. Evolving paradigms in the melanoma treatment landscape: a case based round table discussion. Conference. Evolving paradigms in the melanoma treatment landscape: a case based round table discussion. Houston, TX, US.
- 2018. The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on immune infiltrates in metastatic melanoma. Conference. The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on immune infiltrates in metastatic melanoma. Milwaukee, WI, US.
- 2014. Identification of Kruppel-like factor 6 (KLF6) as a deferentially expressed transcription factor in well differentiated and dedifferentiated liposarcoma through unbiased epigenetic approaches. Conference. Identification of Kruppel-like factor 6 (KLF6) as a deferentially expressed transcription factor in well differentiated and dedifferentiated liposarcoma through unbiased epigenetic approaches. San Francisco, CA, US.
International Presentations
- 2025. SU2C-SARC032 trial: Implications for clinical practice. Invited, US.
- 2023. Evaluation of the masspec pen technology for molecular identification of bone and soft tissue sarcomas and surgical margin assessment. Invited. Connective Tissue Oncology Society Annual Meeting. Dublin, IE.
- 2022. Practice patterns in the management of regional lymph node metastasis in soft tissue sarcoma: a survey of the Society of Surgical Oncology and Musculoskeletal Tumor Society membership. Conference. Practice patterns in the management of regional lymph node metastasis in soft tissue sarcoma: a survey of the Society of Surgical Oncology and Musculoskeletal Tumor Society membership. Vancouver, CA.
- 2022. Defining differentiation states in well-differentiated and de-differentiated liposarcoma. Invited. Connective Tissue Oncology Society Annual Meeting. Vancouver, CA.
- 2022. Patterns of care and outcomes of patients presenting with small gastrointestinal stromal tumors at a high-volume sarcoma center. Invited. Western Surgical Association Annual Meeting. Santa Barbara, US.
- 2022. Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas and undifferentiated pleomorphic sarcomas treated with neoadjuvant nivolumab +/- ipilimumab. Invited. European Society of Medical Oncology Annual Meeting. Paris, FR.
- 2022. Antigen presentation and processing pathway is associated with early relapse after neoadjuvant immune checkpoint blockade in dedifferentiated liposarcoma. Conference. Antigen presentation and processing pathway is associated with early relapse after neoadjuvant immune checkpoint blockade (ICB) in dedifferentiated liposarcoma (DDLPS). Montreal, CA.
- 2022. Prospective single-arm controlled trial of 3-week-course hypofractionated preoperative radiotherapy for soft tissue sarcoma of the extremity or trunk. Invited. European Society of Radiotherapy and Oncology Annual Meeting. Copenhagen, DK.
- 2022. Sarcoma referral centers. Invited. TARPSWG Educational Webinar Series. Virtual Conference.
- 2021. Prospective single-arm controlled trial of 3-week-course hypofractionated preoperative radiotherapy for soft tissue sarcoma of the extremity or trunk. Conference. Virtual Conference.
- 2021. The natural history of gangioneuroma: an international study by the transatlantic Australasian retroperitoneal sarcoma working group. Conference. Virtual Conference.
- 2021. Sentinel lymph node biopsy and lymphadenectomy for soft tissue sarcoma – a single center experience of 86 consecutive cases. Conference. Virtual Conference.
- 2021. Comparative review of human and canine peripheral nerve sheath tumors. Conference. Virtual Conference.
- 2021. Neoadjuvant and adjuvant nivolumab with anti-LAG3 antibody relatlimab for patients with resectable clinical stage III melanoma. Invited. American Society of Clinical Oncology Annual Meeting. Virtual Conference.
- 2020. Surgical management of primary and recurrent melanoma. Invited. 7th International Cancer Symposium. Manila, PH.
- 2013. The microbiology of immunocompromised patients with necrotizing soft tissue infection parallels those with a competent immune system. Invited. Surgical Infections Society Annual Meeting. Las Vegas, US.
- 2012. Predictors of outcomes in patients with retroperitoneal dedifferentiated liposarcoma undergoing surgery. Conference. Prague, CZ.
Formal Peers
- 2024. Management of soft tissue sarcoma. Invited. Houston, Texas, US.
- 2023. Window-of-opportunity trials and neoadjuvant trial. The University of Texas MD Anderson Cancer Center.
- 2023. Mentoring. The University of Texas MD Anderson Cancer Center.
- 2023. Multidisciplinary management of soft tissue sarcoma. The University of Texas MD Anderson Cancer Center.
- 2022. Window-of-opportunity trials and neoadjuvant trials. The University of Texas MD Anderson Cancer Center.
- 2022. Multimodal treatment considerations in the management of soft tissue sarcoma. The University of Texas MD Anderson Cancer Center.
- 2022. Surgical management of soft tissue sarcoma. The University of Texas MD Anderson Cancer Center.
- 2021. Starting a career as a surgeon scientist. The University of Texas MD Anderson Cancer Center.
- 2021. Surgical management of soft tissue sarcoma. The University of Texas MD Anderson Cancer Center.
- 2021. Starting a career as a surgeon scientist. The University of Texas MD Anderson Cancer Center.
- 2020. The surgical management of melanoma. The University of Texas MD Anderson Cancer Center.
- 2020. Extremity sarcoma. The University of Texas MD Anderson Cancer Center.
Grant & Contract Support
| Date: | 2025 - 2027 |
| Title: | Spatially resolved multiomics of primary soft tissue sarcomas and their matched metastases |
| Funding Source: | Society of Surgical Oncology |
| Role: | PI |
| ID: | Clinical Investigator Award |
| Date: | 2024 - 2025 |
| Title: | Elucidation of intratumoral spatial immune features of primary undifferentiated pleomorphic sarcomas associated with metastasis |
| Funding Source: | Society of University Surgeons Early Stage Investigator Award |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Elucidation of Intratumoral Immune Microenvironment Characteristics of Primary Soft Tissue Sarcomas and Their Matched Regional and Distant Metastases |
| Funding Source: | Leiomyosarcoma SPORE |
| Role: | PI |
| ID: | Developmental Research Program |
| Date: | 2024 - 2028 |
| Title: | Physician-Scientist Program |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2023 - 2024 |
| Title: | Assessing the impact of perioperative prophylactic antibiotics and associated gut dysbiosis on systemic immunity in patients undergoing surgery for early-stage melanoma |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | Institutional Research Grant |
| Date: | 2023 - 2025 |
| Title: | A novel uterine leiomyosarcoma mouse model for therapeutic development |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Collaborator |
| ID: | NIH/NCI 1R21CA273661-01A1 |
| Date: | 2023 - 2025 |
| Title: | Assessing the impact of perioperative prophylactic antibiotics and associated gut dysbiosis on systemic immunity in patients undergoing surgery for early-stage melanoma |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | Institutional Research Grant |
| Date: | 2023 - 2025 |
| Title: | Elucidation of tumor-specific B-cell antigens as novel therapeutic targets in soft tissue sarcoma |
| Funding Source: | Society for Immunotherapy of Cancer |
| Role: | PI |
| ID: | Rosenberg Scholar Award |
| Date: | 2022 - 2025 |
| Title: | The interactions between T-regulatory cells and B-cells as new therapeutic targets for immunotherapy in soft tissue sarcoma |
| Funding Source: | National Cancer Institute |
| Role: | PI |
| ID: | Early-Stage Surgeon-Scientist Program |
| Date: | 2022 - 2023 |
| Title: | Evaluating the impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy |
| Funding Source: | Society of Surgical Oncology |
| Role: | PI |
| ID: | Young Investigator Award |
| Date: | 2020 - 2024 |
| Title: | Evaluating the chromatin accessibility landscape as a driver of clinical behavior in primary treatment naïve liposarcoma |
| Funding Source: | Sarcoma Foundation of America |
| Role: | PI |
| ID: | STL Cure Sarcoma Research Award |
| Date: | 2019 - 2021 |
| Title: | Evaluating immune-based subtyping as predictor of response to neoadjuvant immune checkpoint blockade in patients with resectable soft tissue sarcoma |
| Funding Source: | The University of Texas MD Anderson Cancer Center Sarcoma SPORE Career Enhancement Program, QuadW Foundation |
| Role: | PI |
| ID: | Willie Tichenor Fellowship in Sarcoma |
Selected Publications
Peer-Reviewed Articles
- Tomczak K, Patel MS, Bhalla AD, Peterson CB, Landers SM, Callahan SC, Zhang D, Wong J, Landry JP, Lazar AJ, Livingston JA, Guadagnolo BA, Lyu HG, Lillemoe H, Roland CL, Keung EZ, Scally CP, Hunt KK, McCutcheon IE, Slopis JM, Gu J, Scheet P, Wang L, Rai K, Torres KE. Plasma DNA methylation-based biomarkers for MPNST detection in patients with neurofibromatosis type 1 64(1):44-45, 2025.
- Nasr LF, Zoghbi M, Lazcano R, Nakazawa M, Bishop AJ, Farooqi A, Mitra D, Guadagnolo BA, Benjamin R, Patel S, Ravi V, Araujo DM, Livingston A, Zarzour MA, Conley AP, Ratan R, Somaiah N, Lazar AJ, Roland C, Keung EZ, Nassif Haddad EF. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers 16(9):1763, 2024. e-Pub 2024. PMID: 38730715.
- Roland CL, Nassif EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Parra ER, Limb CF, Gaudagnolo BA, Bishop AJ, Ingram D, Wani K, Crosby S, Al Rawi AN, Mathew G, Duncan S, Burton E, Ajami N, Torres KE, Hunt KK, Feig BW, Scally CP, Witt RG, Traweek R, Cope B, Lewis V, Bird J, Wu CC, Mohammad M, Chu RA, Zhang JH, Fridman WF, Damania A, Blay JY, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Shaw K, Lin P, Moon B, Satcher R, Wistuba I, Futreal A, Wargo JA, Somaiah N. Neoadjuvant immune checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/trunk undifferentiated pleomorphic sarcoma. Nature Cancer 5:625-641, 2024. e-Pub 2024.
- Bishop AJ, Mitra D, Farooqi A, Swanson DM, Hempel C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin BS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Guadagnolo BA. Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcoma (HYPORT-STS): updated local control, late-toxicities and patient-reported outcomes. Cancer 131:e35542, 2024. e-Pub 2024.
- Award A, Pal K, Yevich S, Kuban JD, Tam A, Odisio BC, Gupta S, Habibollahi P, Bishop AJ, Conley AP, Somaiah N, Araujo D, Zarzour MA. Safety and efficacy of percutaneous thermal ablation for soft tissue sarcoma metastases to the liver. Cancer, 2024. e-Pub 2024. PMID: 38642369.
- Gingrich A, Wangsiricharoen S, Torres, MB, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar AJ, Wang WL, Roland CL, Hunt KK, Yu W, Torres KE. Clinical variables influencing outcomes in patients with atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): single-institution study of 95 surgical patients. Annals of Surgical Oncology 31(12):7950-7956, 2024. e-Pub 2024.
- Traweek RS, Lyu HG, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF. ASO visual abstract: High community-level social vulnerability is associated with worse recurrence-free survival following resection of extremity and truncal soft-tissue sarcoma. Annals of Surgical Oncology 31(6):4150-4151, 2024. e-Pub 2024. PMID: 38396039.
- Pal K, Awad A, Yevich S, Kuban JD, Tam A, Huang SY, Odisio BC, Gupta S, Habibollahi P, Bishop AJ, Conley AP, Somaiah N, Araujo D, Zarzour MA, Ravin R, Roland CL, Keung EZ, Sheth RA. Safety and efficacy of percutaneous cryoablation for recurrent or metastatic soft tissue sarcoma in adult patients. AJR Am J Roentgenol 223(4):e2431490, 2024. e-Pub 2024.
- Lyu HG, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. High community-level social vulnerability is associated with worse recurrence-free survival after resection of extremity and truncal soft tissue sarcoma. Annals of Surgical Oncology 31(6):4138-4147, 2024. e-Pub 2024. PMID: 38396039.
- Lyu HG, Witt RG, Rajkot N, Keung EZ, Torres KE, Hunt KK, Somaiah N, Lazar AJ, Roland CL, Scally CP. Patterns of care and outcomes of patients presenting with small gastrointestinal stromal tumors at a high-volume sarcoma center 31(13):9258-9264, 2024.
- Gingrich A, Wangsiricharoen S, Torres, MB, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar AJ, Wang WL, Roland CL, Hunt KK, Yu W, Torres KE. ASO visual abstract: Clinical variables influencing outcomes in patients with atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): single-institution study of 95 surgical patients. Annals of Surgical Oncology, 2024. e-Pub 2024.
- Cass, SH, Tobin, J, Seo, YD, Gener-Ricos, G, Keung, EZ, Burton, EM, Davies, MA, McQuade, JL, Lazar, A, Mason, R, Millward, M, Sandhu, S, Khoo, C, Warburton, L, Guerra, VA, Haydon, A, Dearden, H, Menzies, AM, Carlino, MS, Smith, JL, Mollee, P, Burgess, M, Mapp, S, Keane, C, Atkinson, VG, Parikh, SA, Markovic, SN, Ding, W, Call, TG, Hampel, PJ, Long, GV, Wargo, J, Ferrajoli, A. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology 34(9):796-805, 2023. e-Pub 2023. PMID: 37414216.
- Cass, SH, Cope, B, Bishop, AJ, Chiang, YJ, Guadagnolo, BA, Farooqi, AS, Morrison, WH, Witt, RG, Seervai, RN, Garden, AS, Fuller, C, Goepfert, RP, Ross, MI, Gershenwald, JE, Wong, MK, Aung, PP, Keung, EZ, Mitra, D. Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiotherapy and Oncology 188(34):109892, 2023. e-Pub 2023. PMID: 37659660.
- Keung EZ, Krause KJ, Maxwell J, Morris CD, Crago AM, Houdek MT, Kane J, Lewis V, Callegaro D, Miller B, Lazar AJ, Gladdy R, Raut CP, Fabbri N, Al-Refaie W, Fairweather M, Wong SL, Roland CL. ASO Visual Abstract: Sentinel Lymph Node Biopsy for Extremity and Truncal Soft Tissue Sarcomas: A Systematic Review of the Literature. Ann Surg Oncol 30(2):970-971, 2023. e-Pub 2023.
- Witt RG, Voss RK, Lewis VO, Roland CL, Keung EZ. ASO Author Reflections: Variability in management of sarcoma lymph node metastases. Ann Surg Oncol 30(6):3677-3678, 2023. e-Pub 2023. PMID: 36749502.
- Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Ann Surg Oncol 30(2):926-940, 2023. e-Pub 2023. PMID: 36115928.
- Traweek RS, Martin AN, Rajkot NF, Guadagnolo BA, Bishop AJ, Lazar AJ, Keung EZ, Torres KE, Hunt KK, Feig BW, Roland CL, Scally CP. Re-excision after unplanned excision of soft tissue sarcoma is associated with high morbidity and limited pathologic identification of residual disease. Ann Surg Oncol 30(1):480-489, 2023. e-Pub 2023. PMID: 36085392.
- Keung EZ, Hunt KK, Roland CL. ASO Author Reflections: A call for consensus, collaboration and data on the role of sentinel lymph node biopsy for soft tissue sarcoma. Ann Surg Oncol 30(2):968-969, 2023. e-Pub 2023. PMID: 36394686.
- Noh S, Nessim C, Keung EZ, Roland CL, Strauss D, Sivarajah G, Fiore M, Biasoni D, Cioffi SPB, Mehtsun W, Cananzi FCM, Sicoli F, Quagliuolo V, Chen J, Luo C, Gladdy RA, Swallow C, Johnston W, Ford SJ, Evenden C, Tirotta F, Almond M, Nguyen L, Rutkowski P, Krotewicz M, Pennacchioli E, Cardona K, Gamboa A, Hompes D, Renard M, Kollár A, Ryser CO, Vassos N, Raut CP, Fairweather M, Krakorova DA, Quildrian S, Perhavec A, Nizri E, Farma JM, Greco SH, Vincenzi B, Lopez JAG, Solerdecoll MS, Iwata S, Fukushima S, Kim T, Tolomeo F, Snow H, Howlett-Jansen Y, Tzanis D, Nikulin M, Gronchi A, Sicklick JK, Working Group TARS. Retrospective analysis of retroperitoneal-abdominal-pelvic ganglioneuromas: An international study by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg 278(2):267-273, 2023. e-Pub 2023. PMID: 35866666.
- Traweek RS, Martin AN, Rajkot NF, Guadagnolo BA, Bishop AJ, Lazar AJ, Keung EZ, Torres KE, Hunt KK, Feig BW, Roland CL, Scally CP. ASO Visual Abstract: Re-excision after unplanned excision of soft tissue sarcoma is associated with high morbidity and limited pathologic identification of residual disease. Ann Surg Oncol 30(1):492, 2023. e-Pub 2023. PMID: 36245056.
- Keung EZ, Krause KJ, Maxwell J, Morris CD, Crago AM, Houdek MT, Kane J, Lewis V, Callegaro D, Miller B, Lazar AJ, Gladdy R, Raut CP, Fabbri N, Al-Refaie W, Fairweather M, Wong SL, Roland CL. Sentinel lymph node biopsy for extremity and truncal sarcomas: a systematic review of the literature. Annals of Surgical Oncology 30(2):958-967, 2023. e-Pub 2023. PMID: 36307665.
- Nassif EF, Roland CL, Keung EZ. Reflections on the value of multidisciplinary oncology training by a medical oncologist. European Journal of Surgical Oncology 49(5):1046-1047, 2023. e-Pub 2023. PMID: 36631346.
- Anzar I, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H, Meza-Zepeda LA, Keung EZ, Stratford R, Burgess M, Tawbi H, Myklebost O, Clancy T. The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition. Frontiers in Immunology 20(14):1226445, 2023. e-Pub 2023. PMID: 37799721.
- Farooqi A, Yoder AK, Lin HY, Pasalic D, Erasmus J, Wernz C, Mitra D, Zarzour MA, Somaiah N, Conley A, Ratan R, Livingston A, Roland C, Scally C, Keung EZ, Gandhi SN, Guadagnolo BA, Nguyen QN, Bishop AJ. Stereotactic ablative radiation therapy for sarcoma lung metastases: indications for treatment and guidance for patient selection. International Journal of Radiation Oncology S0360-3016(23):08023-9, 2023. PMID: 37914142.
- Keung EZ, Krause KJ, Maxwell J, Morris CD, Crago AM, Houdek MT, Kane J, Lewis V, Callegaro D, Miller B, Lazar AJ, Gladdy R, Raut CP, Fabbri N, Al-Refaie W, Fairweather M, Wong SL, Roland CL. ASO Visual Abstract: Sentinel lymph node biopsy for extremity and truncal soft tissue sarcomas-A systematic review of the literature. Ann Surg Oncol 30(2):970-971, 2023. e-Pub 2023. PMID: 36323987.
- Witt RG, Voss RK, Chiang YJ, Nguyen S, Scally CP, Lin PP, Torres KE, Moon BS, Satcher RL, Hunt KK, Bird JE, Feig BW, Lewis VO, Roland CL, Keung EZ. Practice pattern variability in the management of regional lymph node metastasis in extremity and trunk soft tissue sarcoma: A survey of the Society of Surgical Oncology and Musculoskeletal Tumor Society Membership. Annals of Surgical Oncology 30(6):3668-3676, 2023. e-Pub 2023. PMID: 36723723.
- Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. ASO Visual Abstract: Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Ann Surg Oncol 30(2):941-942, 2023. e-Pub 2023. PMID: 36161369.
- Witt, RG, Voss, RK, Chiang, YJ, Nguyen, S, Scally, CP, Lin, PP, Torres, KE, Moon, BS, Satcher, R, Hunt, KK, Bird, JE, Feig, BW, Lewis, VO, Roland, CL, Keung, EZ. ASO Visual Abstract: Practice pattern variability in the management of regional lymph node metastasis in extremity and trunk soft tissue sarcoma: A survey of the Society of Surgical Oncology and Musculoskeletal Tumor Society Membership. Annals of Surgical Oncology 30(6):3679-3680, 2023. e-Pub 2023. PMID: 36826618.
- Asare EA, Fisher SB, Chiang YJ, Haydu LE, Patel S, Keung EZ, Lucci A, Wargo J, Gershenwald JE, Ross MI, Lee JE. Melanoma metastatic to the adrenal gland: an update on the role of adrenalectomy in multidisciplinary management. J Surg Oncol 128(2):313-321, 2023. e-Pub 2023.
- Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med 12(4):4282-4293, 2023. e-Pub 2023. PMID: 36151848.
- Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol 23(12):1547-1557, 2022. e-Pub 2022. PMID: 36343656.
- Witt RG, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel lymph node biopsy and formal lymphadenectomy for soft tissue sarcoma: A single center experience of 86 consecutive cases. Ann Surg Oncol 29(11):7092-7100, 2022. e-Pub 2022. PMID: 35501583.
- Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
- Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12(1008484), 2022. e-Pub 2022. PMID: 36313661.
- Amaria RN, Postow M, Burton EM, Tezlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611(7934):155-160, 2022. e-Pub 2022. PMID: 36289334.
- Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BA. Outcomes after sphincter-sparing local therapy for anorectal melanoma: 1989-2020. Pract Radiat Oncol 12(5):437-445, 2022. e-Pub 2022. PMID: 35278716.
- Witt RG, Cope B, Chiang YJ, Newhook T, Lillemoe H, Tzeng CD, Chen IB, Fisher SB, Lucci A, Wargo JA, Lee JE, Ross MI, Gershenwald JE, Robinson J, Keung EZ. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol 125(4):719-729, 2022. e-Pub 2022. PMID: 34904258.
- Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol 12:1001150, 2022. e-Pub 2022. PMID: 36324592.
- DiPeri TP, Newhook TE, Day RW, Chiang YJ, Dewhurst WL, Arvide EM, Bruno ML, Scally CP, Roland CL, Katz MHG, Vauthey JN, Chang GJ, Badgwell BD, Perrier ND, Grubbs EG, Lee JE, Tzeng CD, Consortium P. A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients. Surg Open Sci 9:51-57, 2022. e-Pub 2022. PMID: 35663797.
- Witt RG, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. ASO Visual Abstract: Sentinel lymph node biopsy and formal lymphadenectomy for soft tissue sarcoma: A single-center experience of 86 consecutive cases. Ann Surg Oncol, 2022. PMID: 35644862.
- Boyce-Fappiano D, Damron EP, Farooqi A, Mitra D, Conley AP, Somaiah N, Araujo D, Livingston JA, Ratan R, Keung EZ, Roland CL, Guadagnolo BA, Bishop AJ. Hypofractionated radiation therapy for unresectable or metastatic sarcoma lesions provides durable tumor control and effective palliation. Advances in Radiation Oncology 7(3):100913, 2022. e-Pub 2022. PMID: 35647398.
- Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer 150(12):2012-2024, 2022. e-Pub 2022. PMID: 35128664.
- Wang Y, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JE. Evaluation of plasma IL-6 in patients with melanoma as a prognostic and checkpoint immunotherapy predictive biomarker. J Invest Dermatol 142(7):2046-2049.e3, 2022. e-Pub 2022. PMID: 34952092.
- Kochat V, Raman AT, Landers SM, Tang M, Schulz J, Terranova C, Landry JP, Bhalla AD, Beird HC, Wu CC, Jiang Y, Mao X, Lazcano R, Gite S, Ingram DR, Yi M, Zhang J, Keung EZ, Scally CP, Roland CL, Hunt KK, Feig BW, Futreal PA, Hwu P, Wang WL, Lazar AJ, Slopis JM, Wilson-Robles H, Wiener DJ, McCutcheon IE, Wustefeld-Janssens B, Rai K, Torres KE. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol 142(3):565-590, 2021. e-Pub 2021. PMID: 34283254.
- Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open 4(3):e210945, 2021. e-Pub 2021. PMID: 33734413.
- Sloane RS, White MG, Witt RG, Banerjee A, Davies MA, Han GC, Burton E, Ajami N, Simon JM, Bernachez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung EZ, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang LH, Andrews MC, Wargo JA. Identification of micro-RNA-mRNA networks in melanoma and their association with PD-1 checkpoint blockade outcomes. Cancers 13(21):5301, 2021. e-Pub 2021. PMID: 34771465.
- Keung EZ, Rajkot N, Torres KE, Somaiah N, Hunt KK, Feig BW, Scally CP, Ikoma N, Roland CL. Evaluating the impact of surveillance follow-up intervals in patients following resection of primary well-differentiated liposarcoma of the retroperitoneum. Ann Surg Oncol 28(1):570-575, 2021. e-Pub 2021. PMID: 32409969.
- Nassif EF, Maloney N, Conley AP, Keung EZ. Disseminated coccidioidomycosis following COVID-19 mimicking metastatic thoracic relapse of well-differentiated liposarcoma: a case report. Front Med (Lausanne) 8:715939, 2021. e-Pub 2021. PMID: 34589500.
- Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal recurrence is a primary driver of early relapse for patients with sentinel lymph node positive melanoma in the modern therapeutic era. Ann Surg Oncol 28(7):3480-3489, 2021. e-Pub 2021. PMID: 33856603.
- Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
- Petitprez, F, de Reyniès, A, Keung, EZ, Chen, TW, Sun, CM, Calderaro, J, Jeng, YM, Hsiao, LP, Lacroix, L, Bougoüin, A, Moreira, M, Lacroix, G, Natario, I, Adam, J, Lucchesi, C, Laizet, Y, Toulmonde, M, Burgess, MA, Bolejack, V, Reinke, DK, Wani, K, Wang, W, Lazar, A, Roland, CL, Wargo, J, Italiano, A, Sautès-Fridman, C, Tawbi, H, Fridman, WH. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556-560, 2020. e-Pub 2020. PMID: 31942077.
- Keung EZ, Gershenwald JE. Clinicopathological features, staging, and current approaches to treatment in high-risk resectable melanoma. Journal of the National Cancer Institute 112(9):875-885, 2020. e-Pub 2020. PMID: 32061122.
- Tzeng CW, Tran Cao HS, Roland CL, Teshome M, Bednarski BK, Ikoma N, Graham PH, Keung EZ, Scally CP, Katz MHG, Gershenwald JE, Lee JE, Vauthey JN. Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: a multidisciplinary approach. Surg Oncol 34:182-185, 2020. e-Pub 2020. PMID: 32891326.
- Keung EZ, Asare EA, Chiang YJ, Prakash LR, Rajkot N, Torres KE, Hunt KK, Feig BW, Cormier JN, Roland CL, Katz MHG, Lee JE, Tzeng CD. Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. Am J Surg 220(1):140-146, 2020. e-Pub 2020. PMID: 31843190.
- Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, Wang WL, Wargo JA, Tawbi HA. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res 26(6):1258-1266, 2020. e-Pub 2020. PMID: 31900276.
- Maitituoheti M, Keung EZ, Tang M, Yan L, Alam H, Han G, Singh AK, Raman AT, Terranova C, Sarkar S, Orouji E, Amin SB, Sharma S, Williams M, Samant NS, Dhamdhere M, Zheng N, Shah T, Shah A, Axelrad JB, Anvar NE, Lin YH, Jiang S, Chang EQ, Ingram DR, Wang WL, Lazar A, Lee MG, Muller F, Wang L, Ying H, Rai K. Enhancer reprogramming confers dependence on glycolysis and IGF signaling in KMT2D mutant melanoma. Cell Rep 33(3):108293, 2020. e-Pub 2020. PMID: 33086062.
- Chrisinger JSA, Al-Zaid T, Keung EZ, Leung C, Lin HY, Roland CL, Torres KE, Benjamin RS, Ingram DR, Khan S, Somaiah N, Amini B, Feig BW, Lazar AJ, Wang WL. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol 120(3):382-388, 2019. e-Pub 2019. PMID: 31206726.
- Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A 116(44):22246-22251, 2019. e-Pub 2019. PMID: 31611368.
- Keung EZ, Chiang YJ, Voss RK, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44(1):170-177, 2018. e-Pub 2018. PMID: 29208319.
- Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hung KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7(2):e1385689, 2018. e-Pub 2018. PMID: 29308306.
- Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018. PMID: 30249211.
- Keung EZ, Chiang YJ, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer 124(23):4495-4503, 2018. e-Pub 2018. PMID: 30317543.
- Keung EZ, Ikoma N, Benjamin R, Wang WL, Lazar AJ, Feig BW. The clinical behavior of well differentiated liposarcoma can be extremely variable: A retrospective cohort study at a major sarcoma center. J Surg Oncol 117(8):1799-1805, 2018. e-Pub 2018. PMID: 29723411.
- Fiziev P, Akdemir KC, Miller JP, Keung EZ, Samant NS, Sharma S, Natale CA, Terranova CJ, Maitituoheti M, Amin SB, Martinez-Ledesma E, Dhamdhere M, Axelrad JB, Shah A, Cheng CS, Mahadeshwar H, Seth S, Barton MC, Protopopov A, Tsai KY, Davies MA, Garcia BA, Amit I, Chin L, Ernst J, Rai K. Systematic epigenomic analysis reveals chromatin states associated with melanoma progression. Cell Rep 19(4):875-889, 2017. e-Pub 2017. PMID: 28445736.
- Keung EZ, Akdemir KC, Al Sannaa GA, Garnett J, Lev D, Torres KE, Lazar AJ, Rai K, Chin L. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. J Clin Invest 125(8):2965-78, 2015. e-Pub 2015. PMID: 26193637.
- Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L. Dual roles of RNF2 in melanoma progression. Cancer Discov 5(12):1314-27, 2015. e-Pub 2015. PMID: 26450788.
- Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. J Am Coll Surg 218(2):206-17, 2014. e-Pub 2014. PMID: 24315890.
- Iasonos A, Keung EZ, Zivanovic O, Mancari R, Peiretti M, Nucci M, George S, Colombo N, Carinelli S, Hensley ML, Raut CP. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer 119(10):1816-22, 2013. e-Pub 2013. PMID: 23456762.
- Keung EZ, Liu X, Nuzhad A, Adams C, Ashley SW, Askari R. Immunocompromised status in patients with necrotizing soft-tissue infection. JAMA Surg 148(5):419-26, 2013. e-Pub 2013. PMID: 23677405.
- Keung EZ, Liu X, Nuzhad A, Rabinowits G, and Patel V. In-hospital and long-term outcomes after percutaneous endoscopic gastrostomy placement in patients with malignancy. J Am Coll Surg 215(6):777-786, 2012. e-Pub 2012. PMID: 22999329.
- Schorge JO, Muto MG, Lee SJ, Huang LW, Welch WR, Bell DA, Keung EZ, Berkowitz RS, and Mok SC. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Research 60:1361-1364, 2000. e-Pub 2000. PMID: 10728699.
- Traweek RS, Lyu HG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. High community-level social vulnerability is associated with worse recurrence-free survival after resection of extremity and truncal soft tissue sarcoma. Annals of Surgical Oncology 31(6):4138-4147.
Invited Articles
- Denu RA, Dann AM, Keung EZ, Ms N, Nassif Haddad EF. The future of targeted therapy for leiomyosarcoma. Cancers 16(5):938, 2024. e-Pub 2024. PMID: 38473300.
- Westerman MB, Pisters LL, Keung EZ. Non-renal retroperitoneal tumors. American Urological Association Update Series 42:158-168, 2023. e-Pub 2023.
- Witt RG, Lyu H, Keung EZ. The past, present, and future: the evolving role and challenges of surgery in the multimodal management of gastrointestinal stromal tumors. Gastrointestinal Stromal Tumor 6:5, 2023. e-Pub 2023.
- Keung EZ, Gershenwald JE. Surgical management of primary cutaneous melanoma or melanoma at other unusual sites. UpToDate, 2023. e-Pub 2023.
- Nassif EF, Keung EZ, Thirasastr P, Somaiah N. Myxoid liposarcomas: systemic treatment options. Current Treatment Options in Oncology 24(4):274-291, 2023. e-Pub 2023.
- Keung EZ, Gershenwald JE. Metastatic melanoma: surgical management. UpToDate, 2023. e-Pub 2023.
- Gingrich AA, Nassif EF, Roland CL, Keung EZ. The landscape of immunotherapy for retroperitoneal sarcoma. Curr Oncol 30(2):2144-2158, 2023. e-Pub 2023. PMID: 36826126.
- Messina V, Cope B, Keung EZ, Fiore M. Management of skin sarcomas. Surg Oncol Clin N Am 31(3):511-525, 2022. e-Pub 2022. PMID: 35715147.
- Keung EZ, Raut CP, Rutkowski P. The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors. Ann Surg Oncol 27(10):3659-3671, 2020. e-Pub 2020. PMID: 32734368.
- Keung EZ, Somaiah N. Overview of liposarcomas and their genomic landscape. Journal of Translational Genetics and Genomics 3(8), 2019. e-Pub 2019.
- Keung EZ, Wargo JA. The current landscape of immune checkpoint inhibition for solid malignancies. Surg Oncol Clin N Am 28(3):369-386, 2019. e-Pub 2019. PMID: 31079794.
- Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 18(8):775-784, 2018. e-Pub 2018. PMID: 29923435.
- Keung EZ, Balch CM, Gershenwald JE, Halpern AC. The revised AJCC 8th edition melanoma staging system. The Melanoma Letter 36(1), 2018. e-Pub 2018.
- Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies. Ann Surg Oncol 25(7):1814-1827, 2018. e-Pub 2018. PMID: 29500764.
- Keung EZ, Raut CP. Management of gastrointestinal stromal tumors. Surg Clin North Am 97(2):437-452, 2017. e-Pub 2017. PMID: 28325196.
- Keung EZ, Fairweather M, Raut CP. Surgical management of metastatic disease. Surg Clin North Am 96(5):1175-92, 2016. e-Pub 2016. PMID: 27542649.
- Keung EZ, Rai K. H3K9me3 mediated repression of KLF6: Discovering a novel tumor suppressor in liposarcoma using a systematic epigenomic approach. Molecular & Cellular Oncology 3(3):e1093691, 2016. e-Pub 2016. PMID: 27314083.
- Fairweather M, Keung EZ, Raut CP. Neoadjuvant therapy for soft tissue sarcoma. Oncology 30(1):99-106, 2016. e-Pub 2016.
- Keung EZ, Fairweather M, Raut CP. The role of surgery in metastatic gastrointestinal stromal tumors. Curr Treat Options Oncol 17(2):8, 2016. e-Pub 2016. PMID: 26820287.
Review Articles
- Malik N, Krause K, Keung EZ, Lyu HG, Lillemoe H, Scally C, Torres K, Hunt K, Austin M, Roland CL. Optimal surveillance for detecting sarcoma lung metastasis - A systematic review. Surg Oncol Insight 2(1), 2025. e-Pub 2025. PMID: 40191537.
- Torres MB, Leung CH, Zoghbi M, Lazcano R, Ingram D, Wani K, Keung EZ, Zarzour MA, Scally CP, Hunt KK, Conley A, Bishop AJ, Guadagnolo BA, Farooqi A, Mitra D, Yoder AK, Nakazawa MS, Araujo D, Livingston A, Ratan R, Patel S, Ravi V, Lazar AJ, Roland CL, Somaiah N, Nassif Haddad EF. Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience. Front Immunol 16:1567736, 2025. e-Pub 2025. PMID: 40370451.
- Cope BM, Traweek RS, Lazcano R, Keung EZ, Lazar AJ, Roland CL, Nassif EF. Targeting the Molecular and Immunologic Features of Leiomyosarcoma. Cancers (Basel) 15(7):2099, 2023. e-Pub 2023. PMID: 37046760.
- Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, Gronchi A, Roland CL. Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Ann Surg Oncol 29:4376, 2022. e-Pub 2022. PMID: 35224688.
- Traweek RS, Cope BM, Roland CL, Keung EZ, Nassif EF, Erstad DJ. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Front Oncol 12:1006959, 2022. e-Pub 2022. PMID: 36439412.
- Callegaro D, Raut CP, Keung EZ, Kim T, Le Pechoux C, Martin-Broto J, Gronchi A, Swallow C, Gladdy R. Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. J Surg Oncol 123(1):12-23, 2021. e-Pub 2021. PMID: 33022754.
- Keung EZ, Nelson PJ, Conrad C. Genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy 31(2):227-235, 2013. e-Pub 2013.
- Keung EZ, Rajab K, Nelson PJ, Bruns CJ, Conrad C. Suicide gene therapy against cancer 4(9):187-194, 2013. e-Pub 2013.
Editorials
- Witt RG, Roland CL, Keung EZ. ASO Author Reflections: Lymph node disease in soft tissue sarcoma: A problematic clinical dilemma. Ann Surg Oncol 29(11):7101, 2022. PMID: 35486264.
- Keung EZ, Roland CL. ASO Author Reflections: Surveillance after resection of retroperitoneal well-differentiated liposarcoma: A balancing act between earlier recurrence detection, patient anxiety, and health care resource expenditure. Ann Surg Oncol 27(Suppl 3):748-749, 2020. PMID: 32409970.
- Keung EZ, Roland CL. Window-of-opportunity trials: The road forward in soft tissue sarcoma and beyond. Ann Surg Oncol 26(5):1188-1189, 2019. PMID: 30680475.
- Keung EZ, Roland CL. Accurate and reproducible diagnosis of canine soft tissue sarcoma using mass spectrometry: A step in the right direction. Cancer Cell 34(5):697-699, 2018. PMID: 30423292.
- Keung EZ, Tawbi HA. Engineered T cells in synovial sarcoma: persistence pays off!. Cancer Discov 8(8):914-917, 2018. PMID: 30076141.
- Keung EZ, Ashley SW. The appendix: A culprit for BRCA1-associated intraperitoneal cancer?. JAMA 148(3):291, 2013.
Abstracts
- Truong DD, Beird H, Wu CC, Krishnan S, Ingram DR, Keung EZ, Roland CL, Yao WT, Benjamin RS, Somaiah N, Feig B, Ludwig JA. Defining differentiation states in well-differentiated and de-differentiated liposarcoma. Cancer Research 83(7_suppl):6558, 2023. e-Pub 2023.
- Traweek RS, Witt RG, Snyder RA, Nassif EF, Lyu H, Krijgh DD, Smith JM, Tilney GS, Feng C, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Feig BW, Keung EZ, Mericli AF, Roland CL. Social vulnerability is associated with worse survival among patients with extremity and truncal soft-tissue sarcoma. Annals of Surgical Oncology 30(Suppl 1), 2023. e-Pub 2023.
- Cass S, Damania A, Witt RG, Meng XL, Sahasrabhojane P, Bassett R, Shelburne S, Chang HY, Somaiya K, Mungovan K, Malke JC, Matejka BA, Paguinto CF, Fisher SB, Lucci A, Lee JE, Ross MI, Gershenwald JE, Duncan S, Ajami N, Roland CL, Wargo JA, Keung EZ. Impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy. Annals of Surgical Oncology 30(Suppl 1), 2023. e-Pub 2023.
- Gingrich A, Torres M, Ravi V, Ratan R, Keung EZ, Scally C, Lazar A, Wang WL, Roland L, Feig B, Hunt KK, Yu W, Torres K. Clinical variables influencing outcomes in cutaneous leiomyosarcoma: single institution study of 81 patients. Annals of Surgical Oncology 30(Suppl 1), 2023. e-Pub 2023.
- Maitituoheti M, Shi A, Tang M, Ho LL, Kredidieh FY, Terranova C, Galani K, Keung EZ, Creasy CA, Wu M, Chen J, Chen N, Singh AK, Chaudhri A, Anvar NE, Tarrantino G, Yang J, Sarkar S, Jiang S, Malke J, Haydu L, Burton E, Davies MA, Gershenwald JE, Hwu P, Lazar A, Cheah JH, Soule CK, Levine SS, Bernatchez C, Saladi SV, Liu D, Tawbi H, Wargo J, Boland GM, Kellis M. Functional roles of enhancers in immune microenvironment and immunotherapy response. Cancer Research 83(7_suppl):6425, 2023. e-Pub 2023.
- Traweek RS, Witt RG, Nassif EF, Ajami NJ, Mishra AK, Damania AV, Wang WL, Lazar AJ, Keung EZ, Torres KE, Scally CP, Zhang XT, Daniel-MacDougall CR, Wargo JA, Somaiah N, Roland CL. Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade. J ImmunoTher Cancer 10(Suppl 2), 2022. e-Pub 2022.
- Witt RG, Cope B, Seervai R, Chiang YJ, Fisher SB, Lucci A, Gershenwald JE, Wargo JA, Ross MI, Wong MK, Mitra D, Keung EZ. Neoadjuvant systemic therapy for Merkel cell carcinoma: a tertiary referral center experience. Annals of Surgical Oncology 29(Suppl 2):331-544, 2022. e-Pub 2022.
- Keung EZ, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang WL, Guadagnolo AB, Bishop AJ, Hunt KK, Feig BW, Bird JE, Lewis VO, Ratan R, Patel S, McBride K, Liu B, Zelazowska M, Wargo JA, Roland CL, Somaiah N. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma: survival results after 2 years of follow-up and intratumoral B-cell receptor correlates. Journal of Clinical Oncology 40(Suppl 17):11501, 2022. e-Pub 2022.
- Nassif EF, Liu B, Wang WL, Lazar AJ, Ingram D, Wani K, Duncan S, Tate T, Mathew G, Crosby S, Shaw K, Zelazowska M, Feig BW, Torres KE, Hunt KK, Guadagnolo BA, Bishop AJ, Futreal A, Wargo JA, Somaiah N, McBride K, Roland CL, Keung EZ. B-cell receptor repertoire is a dynamic biomarker of survival in sarcoma patients treated with neoadjuvant immune checkpoint blockade. J ImmunoTher Cancer 10(Suppl), 2022. e-Pub 2022.
- Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Ann Oncol 33(Suppl 7):910, 2022. e-Pub 2022.
- Cass S, Witt R, Meng XL, Chang HY, Bassett R, Shelbourne S, Somaiya K, Mungovan K, Gershenwald G, Fisher S, Lucci A, Lee JE, Ross M, Duncan S, Ajami N, Roland CL, Wargo JA, Keung EZ. Evaluating the impact of perioperative antibiotic prophylaxis on the microbiome in patients with cutaneous malignancy. Journal of Clinical Oncology 40(Suppl 16):9602, 2022. e-Pub 2022.
- Nassif E, Keung E, Jiang P, Reuben A, Crosby S, Mathew G, Lazar A, Torres K, Wang WL, Guadagnolo A, Bishop A, Hunt K, Bird J, Lewis V, Conley A, Wargo J, Somaiah N, Roland C. Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas and undifferentiated pleomorphic sarcomas treated with neoadjuvant nivolumab +/-ipilimumab. Annals of Oncology 33(Suppl 7):1229-1230, 2022. e-Pub 2022.
- Bermack C, Hornstein N, Keung EZ, Amaria RN, Prieto VG, Bird JE, Futreal A, McQuade JL. Genomics for histologically indistinguishable tumors: a case of malignant melanotic nerve sheath tumor. Pigment Cell and Melanoma Research 35(1):97-184, 2022. e-Pub 2022.
- Nassif EF, Chelvanambi M, Chen L, Chin WC, Damania A, Keung EZ, Witt R, White MG, Ajami NJ, Wong MC, Somaiah N, Sepesi B, Basu S, Allison JP, Sharma P, McBride K, Fridman WH, Wargo JA, Cascone T, Roland CL. Identifying gut microbial signatures associated with B-cells and tertiary lymphoid structures in the tumor microenvironment in response to immune checkpoint blockade. Journal of Clinical Oncology 40(Suppl 16):2511-2511, 2022. e-Pub 2022.
- Cope B, Witt RG, Chiang YJ, Seervai R, Fisher SB, Lucci A, Wargo J, Lee JE, Farooqhi A, Bishop A, Gershenwald JE, Guadagnolo A, Ross MI, Aung P, Mitra D, Keung EZ. Clinical outcomes of 160 with Merkel cell carcinoma following sentinel lymph node biopsy. Journal of the American College of Surgeons 235(5):S238, 2022. e-Pub 2022.
- Chelvanambi M, Deboever N, Nassif E, Damania AV, Chen L, Leung CH, Chin WC, Keung EZ, Witt RG, White MG, Johnson SB, Wong MC, Mishra AK, Lastrapes MJ, Somaiah N, Kadara H, Basu S, Allison JP, Sharma P, McBride KM, Fridmann WH, Heymach J, Sepesi B, Ajami NJ, Roland CL, Wargo JA, Cascone T. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers. J ImmunoTher Cancer 10(2), 2022. e-Pub 2022.
- Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross, MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Wargo JA, Guadagnolo BA, Mitra DM. Patterns of recurrence in patients with sentinel lymph node-positive melanoma in the post-Multicenter Selective Lymphadenectomy Trial II (MSLT-II) era. Annals of Surgical Oncology 28(Suppl 1):1-162, 2021. e-Pub 2021.
- Mitra A, Somaiah N, Conley AP, Amini B, Lin HH, Sanchez B, Garcia C, Mathew G, Tippen S, Baguley J, Song XS, Andrews MC, Little LD, Tate T, Gite S, Solis L, Keung EZ, Beird H, Kim J, Zhang SJ, Gumbs C, Zhang JC, Cooper Z, Haymaker C, Oberst M, Bernatchez C, Ravi V, Araujo D, Zarzour M, Livingston JA, Roland C, Daw N, Rodriguez-Canales J, Wang WL, Wang LH, Tawbi HA, Lazar AJ, Wistuba I, Soria JC, Benjamin R, Patel S, Hwu P, Futreal A. Immunogenomic correlates of response to combination immune checkpoint blockade in advanced sarcoma. Cancer Research 81(13 (Suppl)), 2021. e-Pub 2021.
- Lyu H, Lillemoe H, Chiang YJ, Torres KE, Hunt K, Feig BW, Keung EZ, Bishop AJ, Guadagnolo BA, Somaiah N, Roland CL, Scally CP. Health-Related Quality of Life in patients with resectable undifferentiated pleomorphic sarcoma treated with neoadjuvant checkpoint blockade in a single institution randomized phase II clinical trial. Journal of Clinical Oncology 40(Suppl 16):11544-11544, 2021. e-Pub 2021.
- Traweek R, Keung EZ, Ajami N, Duncan S, Burton E, Tate T, Callahan K, Ingram D, Wani K, Lazar A, Wang WL, Guadagnolo BA, Bishop A, Wargo J, Somaiah N, Roland CL, Nassif E. Fecal microbiome is associated with toxicity, early relapse and B-cell tumor infiltration in soft-tissue sarcoma patients treated with neoadjuvant immune checkpoint blockade. Annals of Oncology 32(Suppl 7):s1464, 2021. e-Pub 2021.
- Cope B, Witt RG, Chiang YJ, Seervai R, Fisher SB, Lucci A, Wargo JA, Lee JE, Farooqhi A, Bishop A, Gershenwald JE, Guadagnolo BA, Ross M, Aung P, Mitra D, Keung EZ. A single center experience of 98 patients with regionally metastatic Merkel cell carcinoma of known and unknown primary at presentation. Journal of Clinical Oncology 40(Suppl 16):9576, 2021. e-Pub 2021.
- Keung EZ, Nassif EF, Lin H, Lazar AJ, Wang WL, Parra ER, Lima CF, Wistuba I, Guadagnolo BA, Bishop AJ, Lewis V, Torres KE, Hunt KK, Feig BW, Scally CP, Al Rawi AN, Crosby S, Mathew G, Ingram D, Wani K, Wargo JA, Somaiah N, Roland CL. Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma treated with neoadjuvant immune checkpoint blockade. J ImmunoTher Cancer 9(Suppl 2), 2021. e-Pub 2021.
- Keung EZ. Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience. Annual Meeting of the Connective Tissue Oncology Society.
Book Chapters
- Torres MB, Keung EZ. Extremity sarcoma. In: Surgical Oncology Clerkship: A Guide for Senior Medical Students. Springer Nature, 2023.
- Saif A, Farooqi AS, Keung EZ. Radiation in the management of extremity sarcomas. In: Difficult Decisions in Surgery: An Evidence-Based Approach. Springer Nature, 2023.
- Witt RG, Keung EZ. Melanoma. In: Clinical Scenarios in Surgery. 3rd edition. Lippincott Williams & Wilkins, 2023.
- Cope B, Witt R, Feig, R, Keung EZ. Nonmelanoma skin cancer. In: The MD Anderson Surgical Oncology Manual. 7th. Wolters Kluwer, 2023.
- Cope B, Witt R, Keung EZ. Merkel cell carcinoma. In: The MD Anderson Surgical Oncology Manual. 7th. Wolters Kluwer, 2023.
- American College of Surgeons. Extremity Sarcoma. In: Operative Standards for Cancer Surgery, Volume 3, 2022.
- Safa H, Mattei J, Bishop AJ, Keung EZ, Yadugiri S, Davies MA, Gitza Oliva IC. Melanoma. In: The MD Anderson Manual of Medical Oncology. 4th. McGraw-Hill, 2022.
- American College of Surgeons. Retroperitoneal sarcoma. In: Operative Standards for Cancer Surgery, Volume 3, 2022.
- Keung EZ, Naylor MF. Practical management of melanoma. In: Skin Cancer Management - A Practical Approach. 2nd. Springer, 2021.
- Keung EZ, Gershenwald JE, Kirkwood JM, Scolyer RA, Sondak V, Thompson JF, Balch CM. Melanoma prognosis and staging. In: Cutaneous Melanoma. 6th. Springer, 2020.
- Keung EZ, Kirkwood JM, Sondak V, Wargo JA, Amaria RN. Neoadjuvant therapy. In: Cutaneous Melanoma. 6th. Springer, 2020.
- Keung EZ, Grubbs EG. Defining the study cohort: inclusion and exclusion criteria. In: Success in Academic Surgery: Clinical Trials. Springer, 2020.
- Keung EZ, Anupamaa JS, Havens J. Burn management. In: Pocket ICU. 2nd. Lippincott Williams & Wilkins, 2017.
- Mahvi DA, Keung EZ, Raut CP. Multimodality therapy for metastatic gastrointestinal stomal tumor. In: Gastrointestinal Stromal Tumors. Springer, 2016.
- Keung EZ, Nelson PJ, Conrad C. Genetically engineered stem cell therapies targeting gastrointestinal malignancy. In: Stem Cell Therapeutics for Cancer. John Wiley & Sons, 2013.
- Keung EZ, Havens J. Burn management. In: Pocket ICU. 1st. Lippincott Williams & Wilkins, 2012.
- Keung EZ, Pollack RE, Hunt KK, Torres KE. Forequarter amputation. In: Master Techniques in Surgery: Breast Surgery. 2nd. Wolters Kluwer.
- Keung EZ, Gershenwald JE. Clinicopathological features, staging, and current approaches to treatment in high-risk resectable melanoma. In: Cancer of the Skin. 3rd. Elsevier.
Patient Reviews
CV information above last modified November 11, 2025